CRISPR Therapeutics, a biopharmaceutical company dedicated to developing groundbreaking gene-based medicines to treat serious diseases, is proud to announce that members of its senior leadership team are set to take part in fireside chats at several investor conferences in May. Get the chance to hear about the company’s progress and plans for the future directly from the source!
About CRISPR Therapeutics
CRISPR Therapeutics is a pioneering gene editing company that is revolutionizing the way serious diseases are treated. With their proprietary CRISPR/Cas9 platform, they are able to make precise, directed changes to genomic DNA.
To further their mission, CRISPR Therapeutics has established therapeutic programs across a range of diseases, from hemoglobinopathies to oncology, regenerative medicine and rare diseases. They have also partnered with leading companies such as Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. to accelerate their progress.
Headquartered in Zug, Switzerland with research and development operations in Boston and San Francisco, as well as a business office in London, CRISPR Therapeutics is changing the face of medicine.